{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T12:03:55Z","timestamp":1780661035114,"version":"3.54.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,5]]},"DOI":"10.7759\/cureus.110287","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T11:18:10Z","timestamp":1780658290000},"source":"Crossref","is-referenced-by-count":0,"title":["Cardiovascular Biomarkers as a Primary Care Gateway to Early Alzheimer's Disease Detection: The Case for an Integrated Screening Approach"],"prefix":"10.7759","author":[{"given":"Aizhan","family":"Tuleubayeva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70086","article-title":"Lecanemab preferentially binds to smaller aggregates present at early Alzheimer's disease","volume":"21","author":"Fertan E","year":"2025","unstructured":"Fertan E, Lam JY, Albertini G, et al.. Lecanemab preferentially binds to smaller aggregates present at early Alzheimer's disease. Alzheimers Dement. 2025, 21:e70086. 10.1002\/alz.70086","journal-title":"Alzheimers Dement"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2024.01415","article-title":"Progress on early diagnosing Alzheimer's disease","volume":"16","author":"Chen Y","year":"2024","unstructured":"Chen Y, Al-Nusaif M, Li S, et al.. Progress on early diagnosing Alzheimer's disease. Front Aging Neurosci. 2024, 16:1415. 10.3389\/fnagi.2024.01415","journal-title":"Front Aging Neurosci"},{"key":"ref3","unstructured":"Leqembi (lecanemab). U.S. Food and Drug Administration. FDA approves treatment for adults with Alzheimer's disease. (2024). Accessed: May 15, 2026: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-adults-alzheimers-disease."},{"key":"ref4","unstructured":"Kisunla (donanemab). U.S. Food and Drug Administration. FDA approves treatment for adults with Alzheimer's disease. (2024). Accessed: May 15, 2026: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-adults-alzheimers-disease-0."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association workgroup","volume":"20","author":"Jack CR Jr","year":"2024","unstructured":"Jack CR Jr, Andrews JS, Beach TG, et al.. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association workgroup. Alzheimers Dement. 2024, 20:5143-69. 10.1002\/alz.13859","journal-title":"Alzheimers Dement"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders","volume":"324","author":"Palmqvist S","year":"2020","unstructured":"Palmqvist S, Janelidze S, Quiroz YT, et al.. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2020, 324:772-81. 10.1001\/jama.2020.12134","journal-title":"JAMA"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70986","article-title":"Early Alzheimer's diagnosis: U.S. primary care physicians and use of blood biomarkers","volume":"22","author":"Burns JM","year":"2026","unstructured":"Burns JM, Alford S, Coppinger J, Jim\u00e9nez-Mausbach M, Ray S, Pandey H, Laird R. Early Alzheimer's diagnosis: U.S. primary care physicians and use of blood biomarkers. Alzheimers Dement. 2026, 22:e70986. 10.1002\/alz.70986","journal-title":"Alzheimers Dement"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01296-0","article-title":"Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission","volume":"404","author":"Livingston G","year":"2024","unstructured":"Livingston G, Huntley J, Sommerlad A, et al.. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 2024, 404:572-628. 10.1016\/S0140-6736(24)01296-0","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2024.123012","article-title":"Clinical and genetic features of dominant essential tremor in Tuscany, Italy: FUS, CAMTA1, ATXN1 and beyond","volume":"460","author":"Orsucci D","year":"2024","unstructured":"Orsucci D, Tessa A, Caldarazzo Ienco E, et al.. Clinical and genetic features of dominant essential tremor in Tuscany, Italy: FUS, CAMTA1, ATXN1 and beyond. J Neurol Sci. 2024, 460:123012. 10.1016\/j.jns.2024.123012","journal-title":"J Neurol Sci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb8739","article-title":"Glymphatic failure as a final common pathway to dementia","volume":"370","author":"Nedergaard M","year":"2020","unstructured":"Nedergaard M, Goldman SA. Glymphatic failure as a final common pathway to dementia. Science. 2020, 370:50-6. 10.1126\/science.abb8739","journal-title":"Science"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-nutr-071715-050947","article-title":"Homocysteine, B vitamins, and cognitive impairment","volume":"36","author":"Smith AD","year":"2016","unstructured":"Smith AD, Refsum H. Homocysteine, B vitamins, and cognitive impairment. Annu Rev Nutr. 2016, 36:211-39. 10.1146\/annurev-nutr-071715-050947","journal-title":"Annu Rev Nutr"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2023-333009","article-title":"Atrial fibrillation and risk of dementia: a systematic review and meta-analysis","volume":"95","author":"Dmytriw AA","year":"2024","unstructured":"Dmytriw AA, Phan TG, Zerna C, et al.. Atrial fibrillation and risk of dementia: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2024, 95:1050-8. 10.1136\/jnnp-2023-333009","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/498671-cardiovascular-biomarkers-as-a-primary-care-gateway-to-early-alzheimers-disease-detection-the-case-for-an-integrated-screening-approach","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T11:18:11Z","timestamp":1780658291000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/498671-cardiovascular-biomarkers-as-a-primary-care-gateway-to-early-alzheimers-disease-detection-the-case-for-an-integrated-screening-approach"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.110287","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,5]]}}}